Evidence map›Paper›PMID 35364222›Full record

Observational studyOphthalmology2022

The Pediatric Optic Neuritis Prospective Outcomes Study: Two-Year Results.

Stacy L Pineles, Robert J Henderson, Michael X Repka, Gena Heidary, Grant T Liu, Amy T Waldman, Mark S Borchert, Sangeeta Khanna, Jennifer S Graves, Janine E Collinge and 6 more

Open access · greenAbstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Ophthalmology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.8field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. MOGAD Is the Most Common Cause of Isolated Optic Neuritis in Children.Annals of clinical and translational neurology · 2026
    Article
  3. Pediatric multiple sclerosis: Improving outcome through high-efficacy therapies.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2025
    Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 14 institutions in 1 country.

Stacy L PinelesStein Eye Institute at the University of California, Los Angeles, Los Angeles, California. Electronic address: pedig@jaeb.org.
Robert J HendersonJaeb Center for Health Research, Tampa, Florida.
Michael X RepkaWilmer Eye Institute, Johns Hopkins University, Baltimore, Maryland.
Gena HeidaryBoston Children`s Hospital, Harvard Medical School, Boston, Massachusetts.
Grant T LiuChildren's Hospital of Philadelphia, Philadelphia, Pennsylvania.
Amy T WaldmanChildren's Hospital of Philadelphia, Philadelphia, Pennsylvania.
Mark S BorchertChildren's Hospital Los Angeles, Los Angeles, California.
Sangeeta KhannaDepartment of Ophthalmology and Neurology, St. Louis University, St Louis, Missouri.
Jennifer S GravesDepartment of Neurosciences, University of California San Diego, San Diego, California.
Janine E CollingeConnecticut Children`s Medical Center, Farmington, Connecticut.
Julie A ConleyHelen DeVos Children`s Hospital, Grand Rapids, Michigan.
Patricia L DavisProgressive Eye Care, Lisle, Illinois.
Raymond T KrakerJaeb Center for Health Research, Tampa, Florida.
Susan A CotterSouthern California College of Optometry at Marshall B. Ketchum University, Fullerton, California.
Jonathan M HolmesDepartment of Ophthalmology, University of Arizona, Tucson, Arizona.
Pediatric Eye Disease Investigator Group
Jaeb Center for Health Research · USChildren's Hospital of Philadelphia · USEye Care Associates · USChildren's Hospital of Los Angeles · USHelen DeVos Children's Hospital · USJohns Hopkins University · USUniversity of California, Los Angeles · USUniversity of California, San Diego · USConnecticut Children's Medical Center · USMarshall B. Ketchum University · USSaint Louis University · USUniversity of Arizona · USBoston Children's Hospital · USHarvard University · US

Funding

Pediatric Eye Disease Investigator Group Coordinating CenterU10EY011751 · NEI · JAEB CENTER FOR HEALTH RESEARCH, INC. · PI KRAKER, RAYMOND · 1997 to 2018
$75.2M
Pediatric Eye Disease Investigator Group NetworkUG1EY011751 · NEI · JAEB CENTER FOR HEALTH RESEARCH, INC. · PI Raymond Kraker, Stacy Pineles · 2019 to 2026
$53.7M
Pediatric Eye Disease Investigator Group: Chair's OfficeU10EY018810 · NEI · MAYO CLINIC ROCHESTER · PI HOLMES, JONATHAN M · 2009 to 2013
$3.5M
PEDIATRIC EYE DISEASE INVESTIGATOR GROUP: CHAIR'S OFFICEU10EY023198 · NEI · INDIANA UNIVERSITY INDIANAPOLIS · PI WALLACE, DAVID K · 2014 to 2018
$1.4M
NEI NIH HHS U10 EY011751NEI NIH HHS U10 EY018810NEI NIH HHS U10 EY023198NEI NIH HHS UG1 EY011751
6 · The paper itself

Abstract

purposePediatric optic neuritis (ON) is a rare disease that has not been well characterized. The Pediatric ON Prospective Outcomes Study (PON1) was the first prospective study to our knowledge aiming to evaluate visual acuity (VA) outcomes, including VA, recurrence risk, and final diagnosis 2 years after enrollment.

designNonrandomized observational study at 23 pediatric ophthalmology or neuro-ophthalmology clinics in the United States and Canada.

participantsA total of 28 (64%) of 44 children initially enrolled in PON1 (age 3-<16 years) who completed their 2-year study visit.

methodsParticipants were treated at the investigator's discretion. MAIN OUTCOMES MEASURES: Age-normal monocular high-contrast VA (HCVA). Secondary outcomes included low-contrast VA (LCVA), neuroimaging findings, and final diagnoses.

resultsA total of 28 participants completed the 2-year outcome with a median enrollment age of 10.3 years (range, 5-15); 46% were female, and 68% had unilateral ON at presentation. Final 2-year diagnoses included isolated ON (n = 11, 39%), myelin oligodendrocyte glycoprotein-associated demyelination (n = 8, 29%), multiple sclerosis (MS) (n = 4,14%), neuromyelitis optica spectrum disease (NMOSD) (n = 3, 11%), and acute disseminated encephalomyelitis (n = 2, 7%). Two participants (7%; 95% confidence interval [CI], 1-24) had subsequent recurrent ON (plus 1 participant who did not complete the 2-year visit); all had MS. Two other participants (7%) had a new episode in their unaffected eye. Mean presenting HCVA was 0.81 logarithm of the minimum angle of resolution (logMAR) (∼20/125), improving to 0.14 logMAR (∼20/25

conclusionsDespite poor VA at presentation, most children had marked improvement in VA by 6 months that was maintained over 2 years. Associated neurologic autoimmune diagnoses were common. Additional episodes of ON occurred in 5 (18%) of the participants (3 relapses and 2 new episodes).

Indexed as

Multiple SclerosisNeuromyelitis OpticaOptic NeuritisAdolescentChildChild, PreschoolFemaleHumansMaleMyelin-Oligodendrocyte GlycoproteinNeoplasm Recurrence, LocalProspective StudiesRetrospective StudiesVision DisordersMyelin-Oligodendrocyte GlycoproteinNeuro-ophthalmologyPediatric ophthalmologyPediatric optic neuritis

Identifiers

PMID35364222
PMCPMC10357378
OpenAlexW4221004929

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.